Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Aroa Biosurgery Ltd ( (AU:ARX) ) has shared an update.
Aroa Biosurgery has welcomed a decision by the US Centers for Medicare & Medicaid Services that ensures its Symphony wound-care products will remain available for outpatient treatment of diabetic foot ulcers and venous leg ulcers under Medicare at least through the end of 2026. CMS has introduced a three-tier classification for skin substitute products—covered, discretionary and non-covered—with Symphony placed in the discretionary category, allowing Medicare Administrative Contractors to reimburse it on a case-by-case basis while additional clinical data are gathered. Aroa has already completed a randomized controlled trial of Symphony, expects publication in 2026, and intends to submit the findings to Medicare contractors ahead of a year-end 2026 review that will underpin future coverage decisions, a process the company views as validating its clinical strategy and supporting continued access for US patients and clinicians.
The most recent analyst rating on (AU:ARX) stock is a Buy with a A$0.90 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
More about Aroa Biosurgery Ltd
Aroa Biosurgery Limited is a New Zealand–headquartered soft-tissue regeneration company that develops, manufactures and distributes medical and surgical products for complex wound healing and soft tissue reconstruction. Its products are based on the proprietary AROA ECM extracellular matrix bioscaffold derived from ovine forestomach, with more than 7 million devices used globally and a key commercial focus on the United States through a direct sales force and its distribution partner TELABio. The company is listed on the Australian Securities Exchange under the ticker ARX.
Average Trading Volume: 330,971
Technical Sentiment Signal: Hold
Current Market Cap: A$227.7M
Find detailed analytics on ARX stock on TipRanks’ Stock Analysis page.